A new analytical tool called topographic single-cell sequencing can reveal a direct genomic lineage between in situ and invasive tumor subpopulations, which may help decipher how and why some DCIS become invasive.
Bladder cancer patients with tumors smaller than 1 cm could be classified as “very-low-risk,” with recurrences that could arise after the 5-year surveillance period.
Treatment of previously untreated follicular lymphoma with atezolizumab combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study.
With increasing cancer survival, fear of cancer recurrence (FCR) is becoming a prominent clinical issue. FCR is prevalent, distressing, and long-lasting, and can negatively impact patients’ quality of life, use of health services, and adherence to follow-up recommendations. Novel targeted therapies may increase risk of FCR because of longer treatment duration and follow-up, increased prognostic precision, and omission of treatment based on genomic status.
Here, we review the barriers to adherence, including those unique to childhood cancer survivors, and the rationale for distribution of a survivorship care plan. We also discuss advantages and potential limitations of delivering survivorship care plans via web-based platforms, and describe the unique features of one of these platforms, Passport for Care.
Here, in Part 1, we will provide an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation. We will also review the current prognostication systems for primary CNS lymphoma.
This video highlights a study that examined whether systemic paclitaxel concentrations in breast cancer patients were associated with severity and progression of chemotherapy-induced peripheral neuropathy.
The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.
This video reviews endocrine resistance mediated by CDK4/6, FGFR, and PI3K in HR-positive breast cancer, and highlights the latest efforts to inhibit these pathways with novel targeted drugs and combinations.
After undergoing treatment, women with young-onset breast cancer and BRCA mutations had similar survival rates as those women who were not mutation carriers, according to the results of a prospective study.
A 74-year-old man with a medical history of hypertension, hyperlipidemia, and type 2 diabetes mellitus was found lying on the ground by his family and was brought to the emergency department, where he was found to have left facial drooping and weakness. What is the most likely diagnosis?
The EGFR tyrosine kinase inhibitor osimertinib showed promising efficacy and manageable toxicity in patients with advanced NSCLC and CNS metastases.
This video highlights recent studies advancing the field of breast cancer screening and diagnosis, including the potential need for increased surveillance in patients with false positives and patient access to mammography.
This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.
Nearly two-thirds of older patients with stage III lung cancer do not receive any treatment, according to a new study.